Last update 12 Dec 2024
Vislarafusp alfa
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Antibody fusion proteins |
Synonyms IMM2902 |
Target |
Mechanism CD47 modulators(Cluster of differentiation 47 modulators), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationFast Track (US) |
Login to view timeline
Gene Sequence
Sequence Code 454005689H
Source: *****
Sequence Code 454005692L
Source: *****
Related
3
Clinical Trials associated with Vislarafusp alfaA Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors
An Open-label, Multicenter, First-in-human Dose-escalation and Cohort Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMM2902 in the Treatment of HER2-expressing Advanced Solid Tumors
一项开放、多中心、首次人体的剂量递增和队列扩展的I/II期临床研究，旨在评价IMM2902治疗HER2表达的晚期实体瘤的安全性、耐受性和初步有效性
[Translation] An open-label, multicenter, first-in-human, dose-escalation and cohort expansion Phase I/II clinical study designed to evaluate the safety, tolerability and preliminary efficacy of IMM2902 in the treatment of HER2-expressing advanced solid tumors
100 Clinical Results associated with Vislarafusp alfa
Login to view more data
100 Translational Medicine associated with Vislarafusp alfa
Login to view more data
100 Patents (Medical) associated with Vislarafusp alfa
Login to view more data
100 Deals associated with Vislarafusp alfa
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Bile Duct Carcinoma | Phase 2 | CN | 15 Feb 2022 | |
| Advanced gastric carcinoma | Phase 2 | CN | 15 Feb 2022 | |
| HER2-Expressing Cancers | Phase 2 | CN | 15 Feb 2022 | |
| Lung Cancer | Phase 2 | CN | 15 Feb 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 24 Jan 2022 | |
| Advanced breast cancer | Phase 1 | US | 20 Jun 2022 | |
| HER2 Positive Solid Tumors | Phase 1 | US | 20 Jun 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 16 | ywruzsqune(dbxckmpggw) = One SAE (grade 3 gastrointestinal hemorrhage) was reported, which was unrelated to IMM2902. yxwkrhvuan (ajbudzzykp ) | Positive | 31 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free